Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE−/− mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation

Dan Feng 1*, Jun Zou 2, Dongfang Su 3, Haiyan Mai 4, Shanshan Zhang 1, Peiyang Li 1 and Xiumei Zheng 1

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and has become a public health concern worldwide. The hallmark of NAFLD is hepatic steatosis. Therefore, there is an urgent need to develop new therapeutic strategies that are efficacious and have minimal side effects in hepatic steatosis and NAFLD treatment. The present study aimed to investigate the effect of dietary supplement of curcumin on high-fat diet (HFD)-induced hepatic steatosis and the underlying mechanism.

Methods: ApoE−/− mice were fed a normal diet, high-fat diet (HFD) or HFD supplemented with curcumin (0.1% w/w) for 16 weeks. Body and liver weight, blood biochemical parameters, and liver lipids were measured. Intestinal permeability, hepatic steatosis and mRNA and protein expressions of TLR4-related inflammatory signaling molecule were analyzed.

Results: The administration of curcumin significantly prevented HFD-induced body weight gain and reduced liver weight. Curcumin attenuated hepatic steatosis along with improved serum lipid profile. Moreover, curcumin up-regulated the expression of intestinal tight junction protein zonula occluden-1 and occludin, which further improved gut barrier dysfunction and reduced circulating lipopolysaccharide levels. Curcumin also markedly down-regulated the protein expression of hepatic TLR4 and myeloid differentiation factor 88 (MyD88), inhibited p65 nuclear translocation and DNA binding activity of nuclear factor-κB (NF-κB) in the liver. In addition, the mRNA expression of hepatic tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) as well as the plasma levels of TNF-α and IL-1β were also lowered by curcumin treatment.

Conclusion: These results indicated that curcumin protects against HFD-induced hepatic steatosis by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation. The ability of curcumin to inhibit hepatic steatosis portrayed its potential as effective dietary intervention for NAFLD prevention.

Keywords: Hepatic steatosis, Curcumin, Tight junction protein, Lipopolysaccharide, Toll like receptor 4, Nuclear factor-κB
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting 22–28% of the adult population and > 50% of obese individuals worldwide [1]. NAFLD covers a wide spectrum of liver pathologies which range from simple steatosis to non-alcoholic steatohepatitis. The hallmark of NAFLD is hepatic steatosis. Hepatic steatosis is a progression of excessive triglyceride accumulation caused by the imbalance between the influx and synthesis of hepatic lipids on one side and their β-oxidation and export on the other [2]. Many clinical and animal studies have indicated the central role of lipid accumulation in the progression and pathogenesis of NAFLD [3]. Therefore, it is an important step in the prevention of NAFLD to inhibit hepatic steatosis by reducing hepatic lipid accumulation.

The pathogenesis of hepatic steatosis is complex and has been shown to be associated with high-fat diet (HFD), obesity and a sedentary lifestyle, insulin resistance and type 2 diabetes [4]. Toll-like receptor-4 (TLR4) is a pattern recognition receptor of the innate immune system that plays a pivotal role in the innate immunity and inflammatory response [5]. Recent data has shown that TLR4 is also implicated in hepatic steatosis and NAFLD pathogenesis [6]. Loss-of-function TLR4 mutant mice are resistant to diet-induced NAFLD [7]. Ligands for TLR4 include gut-derived endotoxin lipopolysaccharide (LPS) [8], which is increased in different diet-induced rodent models of NAFLD [6]. LPS injections in NAFLD mice further increased proinflammatory cytokines and promoted liver injury [9]. High-fat diet can modify the gut permeability and elevate the serum LPS levels [10], and increased serum LPS can activate hepatic TLR4. Stimulation of TLR4 interacts with its downstream adaptor molecules myeloid differentiation factor 88 (MyD88) to activate nuclear factor-κB (NF-κB) transcription factor, subsequently results in production of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), which propel the inflammatory reaction and cause the hepatic lipogenesis and lipid accumulation [6, 11]. Thus, strategies that reduce TLR4 ligand availability and/or inhibit hepatic TLR4 signaling would be expected to prevent hepatic steatosis.

Curcumin is a natural polyphenolic compound present in turmeric and possesses antiinflammatory, antioxidant and hepatoprotective properties [12, 13]. In recent animal studies, curcumin has been shown to have a protective effects on the liver against fat accumulation induced by a high-fat diet [14, 15]. The exact mechanism by which curcumin reduces liver fat accumulation and alleviates hepatic steatosis is not fully understood. TLR4 plays a pivotal role in hepatic fat accumulation and NAFLD development, several studies have shown that curcumin administration has been involved in the regulation of different inflammatory cytokines including TNF-α and IL-1β through inhibiting the activation of the TLR4/NF-κB signaling pathways [16, 17]. However, whether curcumin can prevents high-fat diet-induced fat accumulation and hepatic steatosis by inhibiting TLR4 signaling is still unknown. Therefore, the objective of this study was to investigate whether curcumin can attenuate HFD-induced hepatic steatosis and suppress NAFLD development in ApoE−/− mice by improving intestinal barrier function and reducing TLR4 ligand availability and suppressing hepatic TLR4-mediated inflammation, as well as further investigate the protective effects of curcumin on atherosclerotic liver injury.

Materials and methods
Chemicals
Curcumin (purity≥98%) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibody against TLR4 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against p65, occludin and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against zonula occluden-1 (ZO-1) and MyD88 were purchased from Abcam (Cambridge, MA, USA). SYBR Green-based real-time PCR kit was purchased from Applied Biosystems (Foster City, CA, USA). TRizol reagent and the cDNA synthesis kit were obtained from Invitrogen Life Technology (Carlsbad, CA, USA). ELISA kits for TNF-α, IL-1β and LPS quantification were purchased from R&D Systems (Minneapolis, MN, USA). TransAM NF-κB p65 ELISA kit was purchased from Active Motif (Carlsbad, CA, USA).

Animals and diets
Eight-week-old male ApoE−/− mice with a C57/BL6 genetic background were obtained from the Beijing Vital River Laboratory Animal Technology Co. Ltd. (Beijing, People’s Republic of China). ApoE−/− mice were fed in stainless steel metabolic cages at 22°C with a 12 h light/dark cycle with free access to food and water. After 1 week of adaptation, the mice were randomly divided into three groups (n = 10). The control group was fed a normal diet with 10% of energy as fat, the high-fat (HF) group was fed a high-fat diet (41% of total calories from fat; 0.15% cholesterol), and curcumin-treated group was fed a high-fat diet supplemented with curcumin (0.1% w/w). The dose of 0.1% curcumin was chosen according to previous study. Hasan et al. showed that curcumin at the medium dose of 0.05–0.1% was effective at reducing serum levels of several inflammatory cytokines [14, 15]. The compositions of the different diets were analysed chemically (Table 1). Following 16 weeks of feeding, the ApoE−/− mice were fasted overnight and then anesthetized. Blood samples were collected and the serum samples were separated by centrifuging the blood at 1500×g for 10 min at 4°C. The entire
liver and intestine were dissected out and weighed, some sections were snap frozen in liquid nitrogen prior to their storage at −80 °C, and some sections were fixed in formalin or in cold acetone for further histological and immunohistochemistry analysis. All animal procedures conducted in this study were approved by the Animal Care and Use Committee of Sun Yat-sen University.

Biochemical analysis
Total lipids were extracted from hepatic tissue according to the method of Bligh and Dyer. After evaporation to dryness under a stream of nitrogen, the lipid extracts were re-suspended in a solution of 90% isopropanol and 10% Triton X-100. The total TG contents in the liver were then quantified using a commercial enzyme kits (BioSino, Beijing, China) on a Biosystem automatic biochemistry analyzer (Madrid, Spain) [18, 19]. Serum total cholesterol (TC) and TG were determined enzymatically by using commercial kits (BioSino, Beijing, China), according to the manufacturer’s recommendations. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were determined with an automatic biochemistry analyzer (Olympus AU600, Tokyo, Japan) [18, 19].

Histological examination
The liver slices were fixed with 10% buffered formalin, embedded in paraffin, cut at thickness of 5 μm and then stained with haematoxylin / eosin (H&E). For Oil Red O staining, livers were embedded in Tissue-Tek OCT, snap frozen and stored at −80 °C. Images were captured using an Olympus BX60 cam er at ×200 magnification. Steatosis was numerically scored following semi-quantitative pathological standard.

Immunohistochemistry
To measure TLR4 expression in the hepatic tissues, immunohistochemical staining was used as previously described [20]. Briefly, liver sections were fixed in cold acetone for 10 min, washed with PBS for three times, and blocked with 3% BSA for 30 min at room temperature. After that, sections were incubated with specific antibodies (TLR4 antibody) overnight at 4 °C, then incubating with biotin-conjugated secondary antibodies, avidin-biotin complex, and DAB as a substrate. Finally, sections were counterstained with haematoxylin and then analysed with a Leica microscope (DM 2500, Leica, Bensheim, Germany).

ELISA analysis
The plasma levels of TNF-α, IL-1β and LPS in the mice were assayed by the corresponding ELISA kits, following the manufacturer’s instructions. NF-κB activity was assayed as previously described [21]. In brief, nuclear extracts from mouse liver tissues were prepared, and the binding of p65 to DNA was measured with the TransAM NF-κB p65 ELISA kit, according to manufacturer’s instructions.

Quantitative real-time PCR
Total RNA was extracted using Trizol reagents from mouse liver tissues. The levels of TNF-α and IL-1β mRNA were quantified by quantitative real-time PCR as previously described [21]. The primer sequences were shown in Table 2. The internal control used GAPDH mRNA.

Western blotting
The protein expression of TLR4, MyD88, ZO-1, occludin and nuclear p65 was detected by Western blotting. The methods for Western blotting was previously described [22]. Briefly, proteins (50 μg) from mouse liver and ileal tissues or nuclear extracts were subjected to 7.5% SDS-PAGE and electrotransferred to a nitrocellulose membrane. The

### Table 1 Composition of the experiment mice diet

| Ingredients (gm%)          | Control | HF   | HF + Curcumin |
|----------------------------|---------|------|---------------|
| Casein                     | 18.95   | 19.47| 19.47         |
| Corn starch                | 35.54   | 4.99 | 4.99          |
| Maltodextrin               | 11.84   | 9.98 | 9.98          |
| Sucrose                    | 18.96   | 34.04| 34.04         |
| Cellulose                  | 4.74    | 4.99 | 4.99          |
| Oil                        | 2.37    | 0.99 | 0.99          |
| Fat                        | 1.90    | 19.97| 19.97         |
| Mixed minerals, g          | 4.24    | 3.5  | 3.5           |
| Mixed vitamins, g          | 0.95    | 1    | 1             |
| Choline bitartrate, g      | 0       | 0.2  | 0.2           |
| Cholesterol, g             | 0       | 0.15 | 0.15          |
| Curcumin, g                | 0       | 0    | 0.1           |
| Energy(kcal/g)             | 3.85    | 4.69 | 4.69          |
| Energy from fat(%)         | 10%     | 41%  | 41%           |
| Energy from carbohydrate (%)| 70%  | 43%  | 43%           |
| Energy from protein (%)    | 20%     | 17%  | 17%           |

The name of the diet and source, manufacturer: Diet MD 12016(10%fat); Diet MD12015 (41%fat); Medicience Ltd., China.
Control, normal diet; HF, high-fat diet; HF + Curcumin, high-fat diet supplemented with curcumin

### Table 2 Primers used in real-time RT-PCR experiments

| Primer Name | Sequence |
|-------------|----------|
| TNF-α-F     | 5′-TGAGCCACGCTGTAGCAAA-3′ |
| TNF-α-R     | 5′-GCTGACCACACTATGGTGTGT-3′ |
| IL-1β-F     | 5′-CAGCTTTGTACAGTGGGAGA-3′ |
| IL-1β-R     | 5′-TTGTCGAGATGCTGTGGTA-3′ |
| GAPDH-F     | 5′-ATGCCGGTGCCGATGATGAG-3′ |
| GAPDH-R     | 5′-CAGAGGTTCGCCAGATGAC-3′ |
membrane was then immunoblotted with specific antibodies (TLR4, MyD88, ZO-1, occludin, p65) and secondary antibodies conjugated with horseradish peroxidase. The loading control used β-actin and LaminB antibody. The bands were visualized using Pierce™ ECL system, and the band density was determined by Image J software (NIH, USA).

**Statistical analysis**
Data are presented as the mean ± standard error of the mean (SEM), all data were analysed with SPSS 25.0 for Windows (SPSS Inc., Chicago, IL, USA). Statistical analysis was performed using the unpaired Student’s t-test to test the mean of two groups, and one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test was applied for comparisons between multiple experimental groups. A value of $P < 0.05$ was considered significant.

**Results**

**Curcumin suppressed HFD-induced body and liver weight gain**
The ApoE−/− mice were fed a normal diet, high-fat diet and high-fat diet supplemented with curcumin for 16 weeks, the group with a normal diet was considered as control group. As shown in Table 3, the high-fat diet-fed mice, compared to controls, markedly gained weight, as well as significantly increased liver weight. Curcumin supplementation induced a significant reduction in body weight gain and liver weight, the body weight gain and liver weight of the curcumin group was significantly lower than that of the high fat (HF) group ($P < 0.05$). There was no difference in food intake among the three groups throughout the experimental period.

**Curcumin improved serum lipid profile in HFD-fed ApoE−/− mice**
As shown in Table 3, compared to control group, high-fat diet-fed mice showed significantly higher levels of serum TC, TG and LDL-C, and lower level of HDL-C. Curcumin treatment improved the high-fat diet-induced dyslipidemia, the levels of serum TC and LDL-C in curcumin group were remarkably lower than that in high fat group ($P < 0.05$), and the level of HDL-C in curcumin group was higher than that in high fat group ($P < 0.05$).

**Curcumin alleviated HFD-induced liver injury**
To determine whether curcumin treatment could attenuate the high-fat diet-induced liver injury, the concentrations of serum ALT and AST were examined. As shown in Table 3, the concentrations of serum ALT and AST in high-fat diet-fed mice were significantly higher than that in normal diet-fed mice. Curcumin administration significantly reduced the high-fat diet-induced elevation in serum AST ($P < 0.05$). Serum ALT in high fat group appeared to be higher than that in curcumin group, but there was no significant difference between the two groups.

**Curcumin attenuated HFD-induced hepatic steatosis**
The histological analyses by H&E (Fig. 1a) or Oil Red O staining (Fig. 1b) showed a remarkable increase of lipid deposition in the livers of high-fat diet-fed mice compared to those of normal diet-fed mice (Control group). Curcumin supplementation significantly reduced the high-fat diet-induced lipid deposition in the livers. Consistent with the results of histological analysis and liver weight, the hepatic TG concentration in curcumin-treated mice was about three fold lower than that in high-fat diet-fed mice (Fig. 1c). The degree of high-fat diet-induced hepatic steatosis was significantly attenuated in curcumin-treated mice, as shown by the decrease in the steatosis scores (Fig. 1d).

**Curcumin reduced serum LPS levels in HFD-fed ApoE−/− mice**
Endotoxin LPS derived from intestine functions as a natural ligand of TLR4 and is closely related with hepatic steatosis and the development of NAFLD [6], we thus examined that the impact of curcumin on circulating LPS levels. Compared to normal diet-fed mice, the serum levels of LPS were dramatically increased in high-fat diet-fed mice and reversed after curcumin administration (Fig. 2).

**Curcumin improved intestinal permeability in HFD-fed ApoE−/− mice**
Since decreased expression of tight junction proteins, such as ZO-1 and occludin, leads to increased intestinal permeability and LPS translocation and plays an important role in the pathophysiology of NAFLD [23], we further determined the influence of curcumin on intestinal permeability. In comparison with normal diet-fed mice, the protein expression levels of ZO-1 and occludin in ileal tissues were markedly down-regulated in high-fat diet-fed mice,
but restored following curcumin administration (Fig. 3a).
To further evaluate the disruption of ileum microstructure, ileal tight junctions were examined by a transmission electron microscope (Fig. 3b). Compared with normal diet-fed mice, intact tight junctions in the ileal tissue were widened in high-fat diet-fed mice, but reversed by curcumin treatment (Fig. 3b and Fig. 3c). These results suggest that curcumin may improve intestinal barrier integrity in high-fat diet-fed mice.

**Curcumin reduced hepatic TLR4 and MyD88 expression in HFD-fed ApoE⁻/⁻ mice**

Activating TLR4 signaling by LPS plays a critical role in the development of NAFLD [6]. To confirm the effects of curcumin on TLR4 signaling in the liver, immunohistochemical staining and Western blot with anti-TLR4 were performed to evaluate hepatic TLR4 and MyD88 expression. Compared to normal diet-fed mice, the immunohistochemical staining showed that the expression of TLR4 in the liver was markedly upregulated in high-fat diet-fed mice, and restored after curcumin administration (Fig. 4a). Consistently, Western blot analysis further indicated that the upregulation of hepatic TLR4 expression induced by high-fat diet was reversed by curcumin treatment. In addition, curcumin supplementation significantly reduced the protein expression levels of hepatic MyD88 compared with high fat group (Fig. 4b).
Fig. 2 Effects of curcumin on circulating LPS levels in HFD-fed ApoE−/− mice. ApoE−/− mice were fed a normal diet, high-fat diet and high-fat diet supplemented with 0.1% curcumin (w/w) for 16 weeks, the serum LPS levels were measured by ELISA. Results are mean ± SEM (n = 10 per group). **p < 0.01 versus control group; ***p < 0.01 versus HF group. Control, normal diet; HF, high-fat diet; HF + Curcumin, high-fat diet supplemented with curcumin.

Fig. 3 Effects of curcumin on intestinal permeability in HFD-fed ApoE−/− mice. ApoE−/− mice were fed a normal diet, high-fat diet and high-fat diet supplemented with 0.1% curcumin (w/w) for 16 weeks. (a) The protein expression of ZO-1 and occludin in ileal tissues was measured by Western blotting. (Top panel) Representative blot, (Bottom panel) Quantitative analysis of panel A. Results are mean ± SEM (n = 10 per group). **p < 0.01 versus control group; *p < 0.05, ***p < 0.01 versus HF group. (b) Ultrastructural observation of the tight junctions in the ileal mucosa and the width of the tight junction gap (transmission electron microscopy, 4000× or 8000×) (n = 10 per group). (c) The width of the tight junction gap (n = 10 per group). *p < 0.05 versus control group; **p < 0.05 versus HF group. Control, normal diet; HF, high-fat diet; HF + Curcumin, high-fat diet supplemented with curcumin.
Curcumin suppressed hepatic NF-κB activation in HFD-fed ApoE−/− mice
Stimulation of TLR4 results in the activation of NF-κB and subsequent transcription of proinflammatory genes [11]. To further insight into the anti-inflammatory effect and mechanism of curcumin, the nuclear translocation and DNA binding activity of NF-κB in the liver were examined. Compared to control group, nuclear proteins from the high fat group demonstrated significantly increased hepatic NF-κB p65 nuclear translocation, but restored following curcumin administration (Fig. 5a). Consistently, the increased DNA binding activity of NF-κB in high-fat diet-fed mice was also reduced by curcumin treatment (Fig. 5b).

Curcumin reduced hepatic TNF-α and IL-1β expression in HFD-fed ApoE−/− mice
TNF-α and IL-1β have been shown to be the important proinflammatory cytokines involved in NAFLD development and can be released subsequently after activation of TLR4/NF-κB signaling pathway [6]. Therefore, we further determined the effects of curcumin on such cytokines. Compared to control group, the mRNA expression levels of TNF-α and IL-1β in
the liver were markedly up-regulated in high fat group (Fig. 6a). Accordingly, the serum TNF-α and IL-1β levels were also increased by high-fat diet (Fig. 6b). Curcumin supplementation significantly reduced hepatic TNF-α and IL-1β expression and serum TNF-α and IL-1β levels induced by high-fat diet.

Discussion
In the present study, we demonstrated that curcumin effectively prevents HFD-induced hepatic steatosis in ApoE−/− mice. Moreover, our results suggest that curcumin treatment significantly inhibits HFD-induced hepatic fat accumulation by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation. To our best knowledge, this is the first in vivo study to reveal the molecular mechanisms of curcumin in preventing hepatic steatosis through modulating the gut-liver axis.

Non-alcoholic fatty liver disease covers a wide spectrum of liver pathologies which range from simple steatosis to non-alcoholic steatohepatitis. Hepatic steatosis is the hallmark of NAFLD and plays an essential role in the progression and pathogenesis of NAFLD [4]. Feeding animals with high-fat diet has been shown to induce obesity, metabolic syndrome and its hepatic manifestation, hepatic steatosis and NAFLD, mimicking the metabolically obese phenotype of Western countries [14, 15, 24]. In our study, HFD feeding induced body weight gain, dyslipidemia and liver lipid accumulation in mice. Hepatic steatosis was the main histopathological finding, as observed in other studies in mice fed a high-fat diet [14, 24, 25]. Oral supplementation with curcumin in HFD-fed mice counteracts increased liver weight by reducing liver steatosis derived from a diminished plasma dyslipidemia and hepatic triglyceride accumulation, suggesting the protective effect of curcumin on HFD-induced hepatic steatosis and NAFLD.

Although curcumin is known to exert positive effects on liver via multiple mechanisms, the precise mechanism responsible for its ability to alleviate liver steatosis remains incompletely defined. Previous research has already indicated that curcumin prevents HFD-induced dyslipidemia and steatosis by means of its modulatory effect on hepatic gene expression related to lipid metabolism, such as regulating AMPK activation and SREBP-mediated lipid biosynthesis [15, 26, 27]. Our current work demonstrated a novel mechanism of curcumin in preventing HFD-induced hepatic steatosis, i.e. to reduced gut-derived endotoxin translocation and hepatic TLR4/MyD88/NF-κB signaling pathway.

Endotoxin LPS derived from intestine functions as a natural ligand of TLR4, and altered TLR4 signaling is a key factor in the pathogenesis of NAFLD [6]. For instance, WT mice fed on a high-fat diet, fructose-rich diet, methionine/choline-deficient diet or choline-deficient amino...
acid-defined diet have shown steatosis/steatohepatitis with increased TLR4 expression and proinflammatory cytokines in the liver [7, 28–30]. Although the mechanism by which these diets induce steatosis is different, these diets modify the gut permeability and elevate the serum LPS levels [31, 32]. Additionally, continuously low-dose LPS injections in WT mice on standard laboratory chow resulted in hepatic weight gain and hepatic steatosis [30]. In contrast, loss-of-function TLR4 mutant mice are resistant to diet-induced NAFLD, even though LPS levels are equivalent to those in WT mice [7]. The plasma LPS levels are also elevated in NAFLD patients [33], and an high-fat diet elevates plasma LPS concentrations and its activity in humans [10, 34]. Thus, the LPS-TLR4 pathway plays a key role in the progression of NAFLD. In this study, we observed that curcumin administration significantly reduced the levels of circulating LPS. We then further examined the influence of curcumin on intestinal tight junction proteins expression such as occludin and zonula occluden-1, which are consistent with gut barrier dysfunction contributing to endotoxemia during NAFLD [23]. Curcumin treatment significantly upregulated ileal occludin and zonula occluden-1 expression along with lower levels of serum LPS and hepatic TLR4 expression. Our results indicated that curcumin prevented the translocation of gut-derived endotoxin LPS by reducing intestinal permeability and then lowered the ligand availability of TLR4, which also support that the anti-inflammatory and anti-NAFLD activities of curcumin occur along the gut-liver axis. In line with our results, several studies have reported that several polyphenols such as quercetin and green tea extract could prevent high-fat diet induced hepatic steatosis by modulating gut-liver axis [35, 36], gut-liver axis will be a potential target for NAFLD treatment.
Stimulation of TLR4 by LPS can interact with its downstream adaptor molecules MyD88 to activate NF-κB transcription factor and then induce the production of proinflammatory cytokines, which propel the inflammatory reaction and cause the hepatic lipogenesis and lipid accumulation. Our current study revealed that curcumin supplementation significantly down-regulated hepatic TLR4 and MyD88 expression, reduced p65 nuclear translocation and NF-κB DNA binding activity, indicating that curcumin suppressed HFD-induced the activation of TLR4-MyD88/NF-κB signaling in the liver, and then prevented liver fat accumulation induced by high-fat diet in ApoE−/− mice. Curcumin has been reported to regulate TLR4 signaling. For instance, Zhou et al. showed that curcumin modulated macrophage polarization by inhibiting TLR4-MAPK/NF-κB signaling pathway [37]. Wang et al. showed that curcumin suppressed LPS-induced sepsis in mice via inhibiting TLR4 signaling activation [38]. Curcumin was also found to exert an anti-inflammatory effect in rat vascular smooth muscle cells through suppressing ROS-related TLR4-MAPK/NF-κB signaling pathway [39], which were consistent with our results.

Activation of TLR4-MyD88/NF-κB signaling results in the subsequent transcription of proinflammatory genes including TNF-α and IL-1β [11]. TNF-α and IL-1β are downstream targets of TLR4/NF-κB signaling and have been shown to promote the progression of NAFLD in animal models [40, 41]. In humans, the expressions of TNF-α and IL-1β as well as their receptor are increased in NAFLD patients [42, 43]. These data indicate that TNF-α and IL-1β are important mediators in the development of NAFLD. TNF-α has been shown to promote triglycerides accumulation in hepatocytes, the mechanisms are considered to be related with impairing insulin signaling. Impairing insulin levels stimulates diglycerides to triglycerides [47]. In the current study, the administration of curcumin significantly reduced the mRNA expression of hepatic TNF-α and IL-1β as well as the serum levels of TNF-α and IL-1β, which were accompanied by reduced inflammation and triglycerides accumulation in the liver. Therefore, the preventive effect of curcumin on hepatic steatosis is mediated, at least in part, by inhibiting hepatic TLR4-MyD88/NF-κB pathway and the subsequent production of TNF-α and IL-1β.

Conclusion

In summary, we demonstrated in this study that dietary curcumin is an effective treatment for HFD-induced hepatic steatosis consistent with a mechanism of modulating the intestinal barrier function and related gut-liver axis activation. This work revealed a new mechanism related to gut-liver axis of curcumin in improving hepatic steatosis and suggested an important clinical application of curcumin in preventing NAFLD and atherosclerotic liver injury.

Abbreviations

ApoE−/−: apolipoprotein E-knockout; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HFD: High-fat diet; HDL-C: High-density lipoprotein cholesterol; H&E: Haematoxylin / eosin; IL-1β: Interleukin-1β; LPS: Lipopolysaccharide; LDL-C: Low-density lipoprotein cholesterol; MyD88: Myeloid differentiation factor 88; NAFLD: Non-alcoholic fatty liver disease; NF-κB: Nuclear factor-κB; TLR4: Toll like receptor 4; TNF-α: Tumor necrosis factor-α; TG: Triglycerides; TC: Total cholesterol; WT: Wild type; ZO-1: Zonula occluden-1

Acknowledgements

Not applicable.

Authors’ contributions

SSZ, PLY, and JZ are involved in the bench work, data acquisition and analysis. DFS, HYM and XMZ perform experiments and data analysis. DF is involved in the design and organization of the study, interpretation of the results, and the preparation of the manuscript. All authors have read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81973019), the Guangdong Medical Science and Technology Research Fund Project (A2018482), and the Guangdong Natural Science Foundation Project (2018A030313782).

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated.

Ethics approval and consent to participate

This study was carried out in strict accordance with the recommendations from the Guide for the Care and Use of Laboratory Animals of the Chinese Association for Laboratory Animal Science. All animal procedures conducted in this study were approved by the Animal Care and Use Committee of Sun Yat-sen University. All killings were performed under sodium pentobarbital anesthesia, and efforts were taken to minimize animal suffering.

Consent for publication

Not applicable.

Competing interests

Conflict of interest On behalf of all authors, the corresponding author states. that there is no conflict of interest.

Author details

1Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Preventive Medicine, School of Public Health, Sun Yat-sen University(Northern Campus), 74 Zhongshan Road 2, Guangzhou 510080, Guangdong Province, China. 2Department of Cardiology, Affiliated Nanhai Hospital of Southern Medical University, Foshan 528200, China. 3Department of Clinic Nutrition, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 4Department of Clinic Nutrition, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Received: 30 July 2019 Accepted: 6 November 2019 Published online: 15 November 2019

References

1. Loomba R, Sanjay AJ. The global NALFD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–90.
2. Frieman SL, Neuschwander-Tetri BA, Rinella M, Sanjay AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.
3. Idilman Is, Gedizen I, Karacalincabu M. Hepatic Steatosis: etiology, patterns, and quantification. Semin Ultrasound CT MR. 2016;37:501–10.
4. Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:23–37.
5. Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediat Inflamm. 2016;2016:6978956.
6. Miura K, Ohnishi H. Role of gut microbiota and toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381–91.
7. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, et al. Deficiency in myeloid differentiation factor 2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011;300:G43–41.
8. Rosadini CV, Kagan JC. Early innate immune responses to bacterial LPS.Curr Opin Immunol. 2017;44:14–9.
9. Kudo H, Takahara T, Yata Y, Kawai K, Wang Z, Sugiyama T. Lipopolysaccharide triggered TNF-alpha induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol. 2009;51:168–75.
10. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:100–1.e1102.
11. Akira S, Takeuchi K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4:499–511.
12. Amatayakul A, Plus A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - a review. J Tradit Complement Med. 2017;7:205–33.
13. Malthillarpagasesili N, Sridhar MG, Swaminathan RP, Sripradha R. Preventive effect of curcumin on inflammation, oxidative stress and insulin resistance in high-fat fed obese rats. J Complement Integr Med. 2016;13:137–47.
14. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatitis in LDL receptor deficient mice. Atherosclerosis. 2014;232:40–51.
15. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol. 2011;108:1315–27.
16. Singh AK, Vineyak M. Curcumin attenuates CFA-induced thermal hyperalgesia by modulation of antioxidant enzymes and down regulation of TNF-alpha, IL-1beta and IL-6. Neurochem Res. 2015;40:463–72.
17. Kong F, Ye B, Cao J, Cai X, Lin H, Huang S, et al. Curcumin represses NLPR3 Inflammasome activation via TRIM32/MOF/NF-kappaB and JNK signaling in LPS-induced macrophages. Front Pharmacol. 2016;7:369.
18. Zou J, Zhang S, Li P, Zheng X, Feng D. Supplementation with curcumin inhibits intestinal cholesterol absorption and prevents atherosclerosis in high-fat diet-fed apolipoprotein E knockout mice. Nutr Res. 2018;38:32–40.
19. Feng D, Zou J, Zhang S, Li X, Li M. Hypocholesterolemic activity of TLC42. J Pharmacol Exp Ther. 2015;353:583–90.
20. Wang Y, Shan X, Dai Y, Liang J, Chen G, Zhang Y, et al. Curcumin analog L48H37 prevents lipopolysaccharide-induced TRAM signaling pathway activation and Sepsis via targeting MD2. J Pharmacol Exp Ther. 2015;353:59–59.
21. Meng Z, Yan C, Deng Q, Dao DF, Niu XL. Curcumin modulates macropage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways. Cell Physiol Biochem. 2015;36:631–41.
22. Wang Y, Shan X, Dai Y, Liang J, Chen G, Zhang Y, et al. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic Biol Med. 2017;102:188–202.
23. Uji I, Saneki GY, Dey P, Chitinchionochochki C, Labyk AN, McDonald JD, et al. Green tea extract protects against hepatic NFκB activation along the gut-liver axis in diet-fed obese mice with nonalcoholic steatohepatitis by reducing endotoxin and TRAM/MOF signaling. J Nutr Biochem. 2018;53:58–65.
24. Zhou Y, Zhang T, Wang X, Wei X, Chen Y, Guo L, et al. Curcumin modulates macrophage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways. Cell Physiol Biochem. 2015;36:631–41.
25. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett. 2008;582:117–24.
26. Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2013;305:G911–8.